Literature DB >> 8149515

Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women.

D W Losordo1, M Kearney, E A Kim, J Jekanowski, J M Isner.   

Abstract

BACKGROUND: The relative absence of coronary atherosclerosis in premenopausal women has been established. Estrogen is presumed to play a role in the protection of coronary arteries from atherosclerosis, and part of this protective effect appears to be mediated by amelioration of serum lipid profiles. However, all of the atheroprotective effect of estrogen is not explained by alteration of serum lipids. In this study, we attempt to identify evidence of estrogen receptors in coronary artery specimens of female patients and in human vascular smooth muscle cells. METHODS AND
RESULTS: Postmortem coronary artery specimens were obtained from premenopausal (n = 18) and postmenopausal (n = 22) women who died with significant coronary artery disease (n = 19) and from noncardiac causes with normal coronary arteries (n = 21). Sections were examined for evidence of estrogen receptor expression using a monoclonal antibody stain. Radioligand binding assays for estrogen receptors were performed on human vascular smooth muscle cells in culture, and gel retardation assays were performed to confirm the presence of functional estrogen receptors. Estrogen receptor expression was identified by immunostaining in a total of 21 coronary arteries, with the majority of normal arteries (15 positive of 21 total, P = .0117) demonstrating evidence of estrogen receptor expression. Conversely, a minority (6 of 19, P = NS) of atherosclerotic arteries were positive for estrogen receptor expression. Furthermore, the relation between estrogen receptor expression and absence of coronary atherosclerosis was most evident in premenopausal subjects, with 10 of 12 normal arteries in this group demonstrating evidence of estrogen receptors, whereas only 1 of 6 atherosclerotic coronary arteries was positive (P = .0062). Radioligand binding assays confirmed the presence of estrogen receptors at significant concentrations in intact human vascular smooth muscle cells. Gel retardation assays also documented the presence of functional estrogen receptors in extracts from human vascular smooth muscle cells.
CONCLUSIONS: This investigation provides evidence of estrogen receptors in smooth muscle cells from human coronary arteries. The demonstrated relation between the presence of the receptors and the absence of atherosclerosis in premenopausal women suggests that these receptors may play a functional role in coronary atheroprotection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8149515     DOI: 10.1161/01.cir.89.4.1501

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  79 in total

1.  Hormone replacement therapy trials: an update.

Authors:  Claire S Duvernoy; Lori Mosca
Journal:  Curr Atheroscler Rep       Date:  2002-03       Impact factor: 5.113

2.  Acute coronary syndrome in women of reproductive age.

Authors:  Nazimah Idris; Sharifah Sulaiha Aznal; Sze-Piaw Chin; Wan Azman Wan Ahmad; Azhari Rosman; Sinnadurai Jeyaindran; Omar Ismail; Robaayah Zambahari; Kui Hian Sim
Journal:  Int J Womens Health       Date:  2011-11-09

Review 3.  Postmenopausal hormone replacement therapy and atherosclerosis.

Authors:  Jennifer E Ho; Lori Mosca
Journal:  Curr Atheroscler Rep       Date:  2002-09       Impact factor: 5.113

Review 4.  What is the cardioprotective role of hormone replacement therapy?

Authors:  Howard N Hodis; Wendy J Mack; Roger Lobo
Journal:  Curr Atheroscler Rep       Date:  2003-01       Impact factor: 5.113

Review 5.  Sex hormone replacement in Turner syndrome.

Authors:  Christian Trolle; Britta Hjerrild; Line Cleemann; Kristian H Mortensen; Claus H Gravholt
Journal:  Endocrine       Date:  2011-12-07       Impact factor: 3.633

Review 6.  Estrogen receptor-α and estrogen receptor-β in the uterine vascular endothelium during pregnancy: functional implications for regulating uterine blood flow.

Authors:  Mayra B Pastore; Sheikh O Jobe; Jayanth Ramadoss; Ronald R Magness
Journal:  Semin Reprod Med       Date:  2012-01-23       Impact factor: 1.303

Review 7.  Impact of sex hormone metabolism on the vascular effects of menopausal hormone therapy in cardiovascular disease.

Authors:  Durr-e-Nayab Masood; Emir C Roach; Katie G Beauregard; Raouf A Khalil
Journal:  Curr Drug Metab       Date:  2010-10       Impact factor: 3.731

8.  E4F1, a novel estrogen-responsive gene in possible atheroprotection, revealed by microarray analysis.

Authors:  Yasuhiro Nakamura; Katsuhide Igarashi; Takashi Suzuki; Jun Kanno; Tohru Inoue; Chika Tazawa; Masayuki Saruta; Tomoko Ando; Noriko Moriyama; Toru Furukawa; Masao Ono; Takuya Moriya; Kiyoshi Ito; Haruo Saito; Tadashi Ishibashi; Shoki Takahashi; Shogo Yamada; Hironobu Sasano
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

9.  Differential Effect of Plasma Estradiol on Subclinical Atherosclerosis Progression in Early vs Late Postmenopause.

Authors:  Intira Sriprasert; Howard N Hodis; Roksana Karim; Frank Z Stanczyk; Donna Shoupe; Victor W Henderson; Wendy J Mack
Journal:  J Clin Endocrinol Metab       Date:  2019-02-01       Impact factor: 5.958

10.  Estrogen inhibits the response-to-injury in a mouse carotid artery model.

Authors:  T R Sullivan; R H Karas; M Aronovitz; G T Faller; J P Ziar; J J Smith; T F O'Donnell; M E Mendelsohn
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.